Sonnet BioTherapuetics(SONN) - 2024 Q3 - Quarterly Results

Exhibit 99.1 Sonnet BioTherapeutics Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update Ongoing progress with both clinical trials of lead program, SON-1010, for solid tumors and Platinum-Resistant Ovarian Cancer (PROC) Partnership ef orts to support initiation of a Phase 2 clinical trial of SON-080 in Diabetic Peripheral Neuropathy (DPN) underway Granted composition of matter patent in key territory – the United States – covering SON-1210 and its application in high-value ...